Expression of Decorin and Mimecan in cervical cancer and their impact on prognostic assessment
- VernacularTitle:Decorin和Mimecan在宫颈癌中的表达及其对预后评估的影响
- Author:
Xingchen LIU
1
;
Fang WANG
;
Yong SHEN
Author Information
- Publication Type:Journal Article
- Keywords: uterine cervical neoplasms; decorin; mimecan; clinical features; prognosis
- From: Tianjin Medical Journal 2025;53(6):578-583
- CountryChina
- Language:Chinese
- Abstract: Objective To explore the expression of core proteoglycans(Decorin)and osteoglycine(Mimecan)in cervical cancer and their relationship with the characteristics of clinical pathological traits and the prognosis of patients.Methods A total of 148 patients with cervical cancer who underwent surgical treatment in our hospital were selected.The expression levels of Decorin and Mimecan were determined by immunohistochemistry(IHC).The positive expression rates of Decorin and Mimecan in patients with different clinicopathological features were compared,and the correlation between the two was analyzed.Cox regression model was used to assess risk factors for death in patients with cervical cancer.Kaplan-Meier survival curve was used to compare the survival rates of patients with positive and negative Decorin and Mimecan expression.Results The positive expression levels of Decorin and Mimecan were both lower in cervical cancer tissue than those in adjacent tissue of cancer(20.0%vs.75.0%,28.3%vs.63.3%,all P＜0.05).The positive expression rates of Decorin and Mimecan were lower in patients with a tumor diameter≥2 cm,FIGO stage Ⅲ-Ⅳ,lymph node metastasis and low tumor differentiation degree compared to those with a tumor diameter＜2 cm,FIGO stage Ⅰ-Ⅱ,no lymph node metastasis and moderately to well tumor differentiation degree(P＜0.05).There was a positive correlation of Decorin and Mimecan in cervical cancer tissue(r=0.686,P＜0.01).Multivariate Cox regression analysis confirmed that negative expression of Decorin(HR=2.365,95%CI:1.236-4.525)and Mimecan(HR=2.191,95%CI:1.322-3.631),FIGO stage Ⅲ-Ⅳ(HR=1.747,95%CI:1.147-2.660)and low tumor differentiation degree(HR=1.577,95%CI:1.035-2.404)were independent risk factors for mortality in cervical cancer patients(P＜0.05).The 5-year survival rate of patients with positive Decorin and Mimecan expression was higher than those with negative expression(79.3%vs.51.3%,73.8%vs.50.0%),and the median survival time was prolonged(75 months vs.60 months,74 months vs.60 months).Conclusion The positive expression rates of Decorin and Mimecan are reduced in cervical cancer tissue and may serve as potential biomarkers for prognostic evaluation of cervical cancer.
